Bordetella hinzii is a commensal respiratory microorganism in poultry but is increasingly being recognized as an opportunistic pathogen in immunocompromised humans. Although associated with a variety of disease states, practically nothing is known about the mechanisms employed by this bacterium. In this study, we show by DNA sequencing and reverse transcription-PCR that both commensal and clinical strains of B. hinzii possess and transcriptionally express cyaA, the gene encoding adenylate cyclase toxin (ACT) in other pathogenic Bordetella species. By Western blotting, we also found that B. hinzii produces full-length ACT protein in quantities that are comparable to those made by B. pertussis. In contrast to B. pertussis ACT, however, ACT from B. hinzii is less extractable from whole bacteria, nonhemolytic, has a 50-fold reduction in adenylate cyclase activity, and is unable to elevate cyclic AMP levels in host macrophages (nontoxic). The decrease in enzymatic activity is attributable, at least in part, to a decreased binding affinity of B. hinzii ACT for calmodulin, the eukaryotic activator of B. pertussis ACT. In addition, we demonstrate that the lack of intoxication by B. hinzii ACT may be due to the absence of expression of cyaC, the gene encoding the accessory protein required for the acylation of B. pertussis ACT. These results demonstrate the expression of ACT by B. hinzii and represent the first characterization of a potential virulence factor of this organism.
There are currently a total of eight members of the genus Bordetella. The four "classical" species, B. pertussis, B. parapertussis, B. bronchiseptica, and B. avium, all cause similar upper respiratory tract infections in a variety of hosts. The strictly human pathogen, B. pertussis, is the causative agent of the disease whooping cough (pertussis) (35) . B. parapertussis causes a milder form of pertussis in humans and sheep. B. bronchiseptica is primarily a veterinary pathogen infecting a wide range of animals, including dogs, rabbits, and horses (29) , whereas B. avium is the etiological agent of bordetellosis in turkeys and other birds (43, 74) .
The remaining four Bordetella species have been discovered in the past decade. B. holmesii has most often been associated with septicemia in patients with underlying disorders (61, 73, 79, 91) but has also been isolated from immunocompetent hosts (60, 68) and nasopharyngeal specimens of patients with pertussis-like symptoms (56, 94) . B. trematum has been isolated from human wounds and ear infections (83) . B. petrii is the only one of the Bordetella species with an environmental reservoir, having been found in an anaerobic bioreactor culture enriched from river sediment (86) . Finally, B. hinzii represents an interesting member of the Bordetella genus, since it has been isolated from both animals and multiple sites within humans. Originally identified as a commensal organism in poultry (84) , B. hinzii has subsequently been isolated from humans in sputum and bronchoalveolar lavage fluid (22, 84) , respiratory secretions (from cystic fibrosis patients) (13, 21) , blood cultures (15, 42) , and bile secretions (2) . A previously misidentified bacterial strain from a rabbit was also confirmed to be the first nonhuman mammalian B. hinzii isolate (65) . Despite being increasingly recognized as an important opportunistic pathogen (22) associated with human disease, virtually nothing is known about the virulence factors employed by this species or the pathogenesis of disease it causes.
The three species (B. pertussis, B. parapertussis, and B. bronchiseptica) whose genomes are completely sequenced and annotated (63) are closely related, maintaining a common set of virulence determinants, including adhesins (fimbriae, filamentous hemagglutinin, and pertactin) and toxins (adenylate cyclase toxin [ACT] , dermonecrotic toxin, and tracheal cytotoxin). B. pertussis also possesses the species-specific pertussis toxin. The bacteria coordinate the differential regulation of virulence gene expression through the two-component regulatory system BvgAS (1, 78) . The inner membrane BvgS sensor recognizes a stimulatory signal, initiating a phosphorelay cascade which culminates in the phosphorylation of the cytoplasmic response regulator, BvgA (81, 82) . Activated BvgAϳP, in turn, binds to DNA sequences within the promoter region and transcriptionally activates the expression of specific virulence genes (7-9, 40, 41, 48, 71) .
Among the genes whose expression is turned on by BvgAS is cyaA, the locus encoding ACT. ACT is a large, modular, bifunctional protein with both adenylate cyclase and hemolytic activities (27, 28) . The C-terminal hemolysin domain is homologous to the RTX (repeats-in-toxin) family of bacterial toxins, while the N-terminal 400 amino acids contain the catalytic domain responsible for enzymatic activity (52) . Once the catalytic adenylate cyclase domain of the toxin enters a susceptible target cell, it binds to and is activated by eukaryotic calmodulin, converting ATP to cyclic AMP (cAMP) (30, 34, 92) .
This ACT-mediated production of supraphysiological levels of intracellular cAMP intoxicates host immune cells, leading to the inhibition of phagocytosis, chemotaxis, and the oxidative burst (14, 20, 64, 87) . In addition to suppressing normal inflammatory cell function, ACT is also capable of promoting apoptotic cell death in macrophages (44, 46) . Presumably by disarming host immune effectors, ACT allows the bacteria to escape host defenses.
In this study, we begin to characterize factors potentially involved in Bordetella hinzii infection, in the hope of augmenting the minimal knowledge of this intriguing organism that can act as both a commensal and a pathogen. We have focused on ACT as a likely candidate in B. hinzii pathogenesis because in other Bordetella species it affects different cell types, possesses multiple important functions, and is essential to virulence (32, 45, 88, 90) . Contrary to a previous report by Gerlach et al. (25) , we have found that B. hinzii expresses cyaA and produces a protein that retains adenylate cyclase enzymatic activity but differs in some other properties relative to the ACT of B. pertussis.
MATERIALS AND METHODS
Bacterial strains and growth conditions. B. hinzii type strain LMG 13501 (84) was purchased from the American Type Culture Collection (no. 51783). BC-306 (42) is a clinical isolate from a septicemia patient and was kindly provided by Brad Cookson (University of Washington). BP338 is a wild-type B. pertussis laboratory strain (89) . B. pertussis was grown on Bordet-Gengou (BG) agar (Difco) containing 10% defibrinated sheep blood (Cocalico) for 3 days at 37°C and modified Stainer-Scholte liquid medium (SSM) (77) at 35.5°C. B. hinzii strains were grown overnight in media identical to those for B. pertussis or on trypticase soy agar (TSA) and broth (TSB) (Difco), as suggested by the source of each strain (American Type Culture Collection) (83, 84) . For growth curves, overnight cultures were diluted into the appropriate media to a starting optical density at 650 nm (OD 650 ) of Ͻ0.1, and aliquots were removed over the time course, serially diluted, and plated on TSA. Plates were incubated overnight at 37°C, and CFU/ml were determined.
General techniques. Genomic DNA was prepared according to the manufacturer's instructions using the DNeasy tissue kit (QIAGEN). All the PCR primers utilized for the presence of cyaA and cyaC were derived from the B. pertussis genomic sequence (GenBank accession numbers Y00545 and M57286, respectively), and reactions were performed with a GeneAmp 2400 (Perkin-Elmer) under empirically determined conditions. Due to the high GC content of Bordetella species, all DNA was amplified with BIO-X-ACT short DNA polymerase (Bioline). PCR products were visualized on 1% ethidium bromide-stained agarose gels with a FOTO/Analyst Investigator Eclipse imaging system (Fotodyne) and purified using the QIAquick kit (QIAGEN) before being sequenced at the University of Virginia Biomolecular Research Facility.
Reverse transcription-PCR (RT-PCR).
Bacterial strains grown in SSM to equivalent cell densities (ϳ3 ϫ 10 9 to 6 ϫ 10 9 bacteria/ml) were centrifuged, and RNA was isolated from the pellets with the Aurum total RNA kit following the manufacturer's protocol (Bio-Rad). DNase-treated RNA (DNA free; Ambion) was run on an agarose gel to verify rRNA band integrity. Equal amounts of RNA (480 ng), as determined by using RiboGreen (Molecular Probes), were added to the iScript cDNA synthesis (Bio-Rad) reaction mixture, and the reaction was carried out in the presence and absence of reverse transcriptase. An equal volume of each cDNA was used as a template for amplification with the following gene-specific primers: cyaA forward, 5Ј-CAACCCCCATTCCACCAG-3Ј, and reverse, 5Ј-GCGAGCGATTTTCCACAAC-3Ј (primers were generated from GenBank accession no. Y00545); ptx forward, 5Ј-ACCGCAAGAACAGGCTG-3Ј, and reverse, 5Ј-GTCGATCGGCATGCTGTTC-3Ј (primer sequences were taken from Kinnear et al. [47] and GenBank accession no. M14378); recA forward, 5Ј-GTCGAACACGACATCCAG-3Ј, and reverse, 5Ј-CCGAGTCGAT GACGATCAG-3Ј (primers from GenBank accession no. X53457); and cyaC forward, 5Ј-CGACGACTTCGCGGCACTG-3Ј, reverse-A, 5Ј-CATAGGAGAG TTCGGTGTCG-3Ј, and reverse-B, 5Ј-TCAGGCGGTGCCCCGGCC-3Ј (primers were from GenBank accession no. M57286). PCR products were electrophoresed on 1% or 2% agarose gels, stained with ethidium bromide, detected with a Fotodyne imaging system, and quantitated with ImageQuant 5.2 software (Molecular Dynamics). Band intensities were normalized to recA, a non-bvgregulated housekeeping gene (49, 57) . Similar results were also obtained using sodB (48) as the normalizing standard. Mock reactions in the absence of reverse transcriptase produced no PCR product, indicating the absence of contaminating genomic DNA in the RNA preparations. We ensured that the number of rounds of PCR chosen was suitable by removing aliquots at different cycles, quantitating product band intensities, and determining the linear portion of the PCR amplification curve.
Protein preparation and Western blotting. Strains were grown to logarithmic phase in the appropriate medium (SSM for BP338 and TSB for B. hinzii). An aliquot (1 ml) of each was centrifuged, and the bacterial pellet was resuspended in 1 ml of fresh medium. Equal lysate volumes were solubilized, electrophoresed on sodium dodecyl sulfate (SDS)-polyacrylamide Criterion gels (Bio-Rad), transferred to polyvinylidene difluoride (PVDF; Osmonics, Inc.), probed with polyclonal ACT antiserum (1:1,000 dilution) and goat anti-rabbit horseradish peroxidase-conjugated immunoglobulin G (Jackson ImmunoResearch), and detected chromogenically with 4-chloro-1-naphthol substrate.
ACT purification. Each strain was grown in 1 liter of SSM, 0.2 mg/ml thimerosol was added, and bacteria were centrifuged at 13,000 ϫ g (9,000 rpm) for 50 min. Pellets were resuspended in 20 ml medium, sonicated on ice in seven 1-min bursts, mixed with 4 M urea, and rotated overnight at 4°C. Suspensions were centrifuged at 27,000 ϫ g (15,000 rpm) for 1 h, and the urea-extracted supernatants were diluted 1:4 in 50 mM Tris, pH 7.5, to reduce the final urea concentration to 1 M. To this material, 1 mM CaCl 2 and 1 ml of prewashed calmodulinSepharose 4B (Amersham) was added and rotated overnight at 4°C. Columns were packed, nonspecific proteins were washed off with 50 mM Tris, pH 7.5, 0.5 M NaCl, 1 mM CaCl 2 , and ACT was eluted in a TEE/8 M urea buffer (TEE ϭ 10 mM tricine, pH 8.0, 0.5 mM EGTA, 0.5 mM EDTA). Purification fractions were solubilized, and ACT was detected in Western blot assays as described above. Full-length ACT protein bands were quantitated with ImageQuant 5.2 software. Protein concentrations were determined with a BCA protein assay kit (Pierce). The Blue-Sepharose purification scheme was essentially the same except reconstituted and prewashed Blue-Sepharose CL-6B (Sigma) replaced calmodulin (CaM)-Sepharose as the column matrix.
Adenylate cyclase enzymatic activity. Adenylate cyclase enzymatic activity was measured by the conversion of [
32 P]ATP to [ 32 P]cAMP in a cell-free system as previously described (38) . Briefly, each sample contained purified ACT diluted into a buffer containing 60 mM tricine, 10 mM MgCl 2 , 2 mM ATP, 1 M calmodulin, and approximately 2 ϫ 10 5 cpm of [␣-32 P]ATP at pH 8.0. Reactions were carried out at 30°C for 10 min and terminated by adding a stop solution (1% SDS, 20 mM ATP, and 6.24 mM cAMP with 2 ϫ 10 4 cpm of [ 3 H]cAMP). Radiolabeled cAMP was separated and measured by the double column method of Salomon et al. (70) . Final urea concentration in the buffer control was approximately 1 M and ranged from 1 mM to 100 mM in the experimental samples.
Intoxication. J774A.1 cells (murine macrophage cell line) were grown to ϳ80% confluence in 24-well tissue culture plates in Dulbecco's modified Eagle's medium with high glucose (Gibco) plus 10% heat-inactivated fetal bovine serum (Gibco) at 37°C in 5% CO 2 . Cells were washed with Hank's balanced salt solution (HBSS; Gibco), purified ACT was added at various concentrations, and the total final volume was adjusted to 1 ml/well with HBSS. Cells were incubated for 1 h at 37°C in 5% CO 2 and then washed three times with cold HBSS and lysed by incubation with 0.1 N HCl at room temperature for at least 30 min. Cells and cellular debris were pelleted by centrifugation, and intracellular cAMP from the supernatant was determined by radioimmunoassay (10) .
Blue-Sepharose binding. The binding of ACT to Blue-Sepharose was performed basically as described by Ladant (50) . Briefly, purified ACT was diluted 10-fold in a buffer consisting of 50 mM Tris-HCl, pH 8.0, 0.1 mM CaCl 2 , 0.1% Nonidet P-40, and 20% glycerol. An aliquot (200 l) was mixed with 10 l prewashed Blue-Sepharose CL-6B in the absence or presence of 100 nM calmodulin at 4°C for 5 h. Tubes were centrifuged, and ACT enzyme activity in the supernatants was measured. Total activity was determined by incubating equivalent toxin samples with CaM in the absence of Blue-Sepharose, under the same conditions.
Nucleotide sequence accession numbers. B. hinzii type (accession no. DQ007078) and BC-306 (accession no. DQ102773) cyaA and type (accession no. DQ141547) and BC-306 (accession no. DQ141548) cyaC DNA sequences were deposited in GenBank.
as B. avium, B. bronchiseptica, or Alcaligenes species (13, 65) , due to their similar biochemical profiles (2, 42) . More recently, however, it has been shown by whole-cell protein patterns and rRNA ribotyping that genetically, B. hinzii is most closely related to B. bronchiseptica and B. parapertussis (21, 42, 84) . Using the B. hinzii type strain isolated from a chicken trachea (LMG 13501, herein referred to as B. hinzii type) (84) and a clinical isolate, BC-306 (42), we have observed that both strains grow well in liquid and semisolid media. Colonies were visible after overnight incubation (16 to 20 h) at 37°C on TSA. On BG agar supplemented with blood, colonies were raised, gray/white, and nonhemolytic. This differs from the hemolytic colony phenotype attributed to ACT production in B. pertussis and B. bronchiseptica. Both strains were indistinguishable from other Bordetella species in a Gram stain, appearing as small, lightly stained gram-negative coccobacilli.
In order to determine which laboratory media would sustain B. hinzii growth, we cultured each strain in peptone-rich TSB and chemically defined SSM designed for B. pertussis (77) . As shown in the growth curves in Fig. 1 , the B. hinzii strains grew equivalently to each other and consistently reached higher OD values in TSB than SSM (Fig. 1A) . There was no discernible difference in the number of live bacteria between the two liquid media at early time points, but after 11 h there were twoto fourfold fewer viable bacteria grown in SSM relative to TSB (Fig. 1B) . This difference in bacterial density during stationary phase may indicate that nutrients necessary for B. hinzii growth are scarce or depleted more readily in SSM than in the nutrient-rich TSB.
cyaA expression. Although the existence of B. hinzii isolates has been known for many years, there remains a paucity of data on the components expressed by this microorganism. We investigated whether B. hinzii possesses cyaA, since this gene encodes a protein (ACT) that is both conserved among most pathogenic bordetellae (16, 75) , with the exception of B. avium, and required for virulence (32, 45, 88, 90) . We amplified overlapping cyaA PCR fragments from BP338, B. hinzii type, and BC-306 chromosomal DNA and sequenced both strands of the products. The sequences of cyaA in all three strains were identical to each other (GenBank accession no. DQ007078 and DQ102773), as well as to the whole genomederived sequence from B. pertussis strain Tohama I (63). Sequence identity encompassed the entire cyaA coding region plus additional DNA upstream to bp Ϫ305, relative to the B. pertussis cyaA transcriptional start site (53). Thus, not only are there no mutations within the cyaA structural gene, but the putative promoter carrying all regulatory elements (ribosome binding site, Ϫ10 Pribnow box, and Ϫ35 region) appears intact.
To ensure that cyaA is not a cryptic or pseudogene in B. hinzii, we performed RT-PCR assays. Gene-specific PCR primers were used to amplify cDNA synthesized from RNA isolated from B. hinzii type, BC-306, and BP338 grown to equivalent bacterial concentrations. As depicted in Fig. 2 and Table 1 , both B. hinzii strains expressed cyaA, although there appeared to be a considerable difference in transcript levels between the two strains. While the amount of the internal control recA mRNA was comparable between B. hinzii type and BC-306, cyaA transcription was greater than twofold higher in BC-306 than B. hinzii type. Due to the difference in visible recA product between B. hinzii and B. pertussis, when cyaA expression was normalized to this housekeeping gene (49, 57) , there was slightly more, but not statistically significantly more (P Ͼ 0.3), relative cyaA production in the B. hinzii strains (Table 1) . Whether this represents a true differential expression of cyaA between the species or is due solely to the decreased basal level of recA in B. hinzii is unclear. As a control for RNA cross-contamination between strains, we also assessed ptx expression, a B. pertussis-specific gene. As expected, ptx was only expressed from BP338 (Fig. 2) . We concluded from these data that commensal and clinical isolates of B. hinzii contain a chromosomally located cyaA gene that is both intact and transcriptionally active.
ACT protein production, purification, and activity. (Fig. 4) . However, when compared to ACT purified from B. pertussis (BP338) under the same conditions, there were some noticeable differences. First, although the starting culture for each strain contained roughly an equal number of bacteria, there was far less full-length ACT protein extracted from B. hinzii than BP338. Secondly, the B. hinzii ACT appeared to bind CaM less well than its BP338 counterpart. When quantitated, the amount of full-length ACT in the unbound fraction accounted for less than 10% of the BP338 ACT total, whereas an equal proportion of B. hinzii type ACT was detected in the unbound void volume as the first elution fraction. Thus, almost 40% of the total B. hinzii ACT extracted never bound the CaM-Sepharose matrix.
Two distinct B. pertussis ACT structural domains bestow functionally independent activities on the toxin: hemolytic and adenylate cyclase enzymatic activities (69) . The former is measured as the lysis of erythrocytes (18) , while the latter represents the toxin's ability to catalyze ATP into cAMP (34, 92) . The in vitro conversion of ATP to cAMP in a cell-free system is enzymatic activity. This is distinguished from the process of intoxication, also called toxin activity, whereby a portion of ACT must interact with and enter eukaryotic target cells in order to elicit increases in host intracellular cAMP pools (39) . We evaluated B. hinzii-purified ACT in these established ACT biological assays (Fig. 5) . The urea-containing buffer in which ACT was eluted and stored postpurification (see Materials and Methods) served as a control in each assay. ACT from B. hinzii strains exhibited a low, but consistent and reproducible, enzymatic activity in the presence of CaM that was 50-fold less than BP338 ACT (P Ͻ 0.002) (Fig. 5A) . This corresponds to a specific activity of ACT from each B. hinzii strain of approximately 0.2 mol/min/mg of toxin protein.
Interestingly, these B. hinzii ACT samples did not increase cAMP levels in host macrophages (Fig. 5B) . Over a 1,000-fold range, BP338 ACT intoxicated in a concentration-dependent manner, whereas B. hinzii ACT activity remained equivalent to the buffer control. Increasing the length of time ACT was incubated with target cells also had no effect on B. hinzii ACT 4 . CaM-Sepharose purification of ACT. Equal volumes of each column fraction were electrophoresed on 10% SDS-polyacrylamide gels, transferred to PVDF, and probed with polyclonal rabbit anti-ACT serum. Proteins were detected chromogenically. All BP338 and B. hinzii type fractions were processed on the same gel, while the BC-306 purification was run separately. V, void volume; W, wash; E1 to -3, elutions; Std, Precision Plus dual color protein standards with sizes in kDa to the right; arrow, full-length ACT. intoxication and even decreased the resultant intracellular cAMP concentrations produced by BP338 ACT (data not shown). This was consistent with previous studies (66; unpublished data) that indicated maximum intracellular cAMP generated by ACT occurs within 30 to 60 min and then readily diminishes. Unsurprisingly, these ACT preparations were also nonhemolytic. Considering the much higher concentration of ACT required to lyse erythrocytes (18) versus the amount needed to intoxicate cells and the observation that B. hinzii colonies were nonhemolytic on blood-containing plates, it was not unexpected that there was no measurable hemolytic activity in vitro.
Taken together, these results provide evidence that B. hinzii, in accordance with B. pertussis, produces a full-length ACT protein that binds CaM and retains some enzymatic activity. In contrast to B. pertussis, the amount of extractable B. hinzii ACT and its apparent affinity for CaM are lower. In addition, B. hinzii does not exhibit any toxin activity and has an approximately 50-fold reduction in adenylate cyclase enzyme specific activity relative to B. pertussis.
Calmodulin binding. Based upon the observations that (i) B. hinzii ACT exhibits decreased enzymatic activity (Fig. 5A) and (ii) a large proportion of protein is found in the unbound fraction during the calmodulin-Sepharose purification (Fig. 4) compared to ACT purified from B. pertussis, we hypothesized that one difference between the two toxins is their respective affinities for CaM. Calmodulin is the eukaryotic protein that binds within a subdomain of the N terminus of B. pertussis ACT and stimulates its adenylate cyclase activity (51, 92) . To address this affinity issue, we evaluated binding of ACT to Blue-Sepharose, a reactive dye matrix that interacts with proteins through their nucleotide binding sites (54, 80) . This method has been previously utilized to determine ACT binding affinities based on the differential binding ability of ACT for Blue-Sepharose in the presence and absence of CaM (50) . Basically, if ACT has a high affinity for CaM then this interaction precludes the binding of ACT to Blue-Sepharose and the toxin remains in the supernatant fraction when the matrix is centrifuged. We incubated B. pertussis or B. hinzii type ACT with Blue-Sepharose with or without CaM, centrifuged the samples, and used enzyme activity as a marker for the distribution of ACT. As shown in Fig. 6 , BP338 ACT had a significantly (P Ͻ 0.005) greater proportion of its measurable ACT activity complexed to CaM in the supernatant fraction (81 Ϯ 1.4%) than B. hinzii ACT (43 Ϯ 1.4%) in 5 h. This defect in binding capacity by B. hinzii was not overcome by increasing the length of time ACT was allowed to interact with the ligands (data not shown).
It is believed that calmodulin is able to activate ACT by binding to the toxin with a high affinity (0.2 nM), causing a conformational change in a flexible loop between the ATPand CaM-binding subdomains and bringing together the amino acids necessary for ACT to bind and catalyze ATP into cAMP (23, 26) . In an attempt to corroborate our Blue-Sepharose competition results, we compared the calmodulin activation between ACT from both Bordetella species. In order to accomplish that goal, we needed an alternative ACT purification method to preclude exposure of ACT to CaM prior to the AC enzymatic assay. Having determined that ACT will bind BlueSepharose, albeit less well than to CaM, we purified ACT from on October 1, 2017 by guest http://jb.asm.org/ BP338 and B. hinzii type using Blue-Sepharose affinity chromatography. Each toxin was assayed for enzymatic activity both in the absence and presence of CaM. In agreement with previous studies that indicated ACT can be activated 100 to 1,000-fold upon CaM binding (92), in Table 2 it is shown that BP338 ACT displayed an approximately 450-fold stimulation in generating cAMP from ATP in the presence of CaM. However, only a 15-fold increase in enzyme activity was observed with purified ACT from B. hinzii. These combined findings suggest that B. hinzii-derived ACT may have a lower affinity for CaM, the established eukaryotic activator of B. pertussis ACT enzyme activity. cyaC expression. The production of fully active ACT is dependent on the palmitoylation of the protein at Lys-983 (33) . This posttranslational modification is catalyzed by the acyltransferase encoded by cyaC (4). It is well established that in the absence of CyaC, ACT is devoid of hemolytic activity and impaired in intoxication functions while retaining enzymatic activity (4, 6, 72) . We investigated whether B. hinzii carries the cyaC locus by using PCR amplification of chromosomal DNA followed by DNA sequencing. As was the case with cyaA, B. hinzii type and BC-306 each possess a full-length copy of cyaC with corresponding upstream sequence that perfectly matches BP338 and Tohama I sequence (GenBank accession no. DQ141547 and DQ141548, respectively). However, unlike cyaA, when we measured cyaC mRNA transcription there was no detectable expression from either B. hinzii strain under conditions in which B. pertussis cyaC expression was visible (Fig. 7) . Two cyaC primer sets, which were also used for sequencing the gene, were employed to ensure that the lack of product was not due to mRNA size or secondary structure. In addition, the same cDNA stocks used for these experiments were also used to generate the data in Fig. 2 , confirming that the templates were present, competent, and able to yield detectable products in an RT-PCR assay. These data suggest that although B. hinzii maintains the cyaC DNA sequence, the lack of gene expression may be the cause of the nontoxic ACT phenotype observed.
DISCUSSION
Given the increase in the incidence and the broadening spectrum of human diseases associated with Bordetella hinzii infection (2, 13, 15, 21, 22, 42, 84) , it was startling to discover that the data on the bacterial determinants of virulence are limited to lipopolysaccharide (LPS) structure (3, 11, 85) . The lack of research has probably been due, in part, to misidentification of the organism (65) and an early publication by Gerlach et al. that indicated that B. hinzii does not possess any of the virulence factors common to the other Bordetella species (25) . More recently, however, these same authors have found genes in B. hinzii, B. holmesii, and B. trematum that they had previously reported to be missing (24) . Additionally, in B. avium, three genes (fhaB, bvgS, and fimC) that were originally thought to be absent from the genome have also been identified (76) . Thus, it was not surprising that in this study we were able to identify cyaA in the B. hinzii chromosome. Given that the GϩC contents of the B. hinzii and B. pertussis genomes are similar (66 to 67% and 67.7%, respectively) (63, 83, 84) , the presence of cyaA in B. hinzii may be the norm, rather than the exception, and a predictor of the existence of other Bordetella virulence genes in B. hinzii.
The DNA sequence of B. hinzii cyaA is identical to the (12, 58, 59) , the cyaA DNA sequence lacks polymorphisms among B. pertussis isolates (62) and is highly homologous between Bordetella species, with a greater than 97% identity between B. pertussis and B. bronchiseptica or B. parapertussis (63) . In order to characterize the properties of B. hinzii ACT, we initially purified the protein using established techniques, including urea extraction and calmodulin affinity chromatography (Fig. 4) . Interestingly, when compared to BP338-derived ACT, there was much less ACT extracted from the B. hinzii strains. Our data indicate that this reduction in protein levels cannot be attributed to a decrease in gene transcription or total amount of ACT made within the bacterium. When normalized to recA, B. hinzii cyaA mRNA expression was not appreciably different than that from BP338 ( Fig. 2 and Table 1 ). In addition, when we solubilized whole bacteria and probed for ACT in a Western blot assay (Fig. 3) , the amounts of full-length ACT between BP338 and B. hinzii were comparable. Thus, there does not seem to be a difference in gene expression or mRNA stability or a defect in the translation of RNA into protein between the species.
Two other possibilities exist to explain this posttranscriptional difference in B. hinzii ACT protein amounts. First, we have recently shown that ACT localization can vary among B. pertussis strains (31), and so it is possible that in B. hinzii a majority of ACT is released into the culture medium instead of being attached to the bacterial surface and is, thereby, subsequently lost during the purification procedure. Secondly, since the purification scheme is optimized for B. pertussis, there may be points at which B. hinzii ACT is preferentially affected. Our preliminary data refute the former and support the latter theory. Although we were able to detect some ACT in the medium of growing B. hinzii cultures, it was only after concentrating the material and, even then, the quantity did not account for the observed differences during purification. On the other hand, we did observe that a significant portion of B. hinzii ACT remained in the insoluble fraction after sonication and urea extraction of the bacteria (data not shown). Given that the structure of B. hinzii ACT is presumably the same as B. pertussis ACT based on sequence data, this may reflect a difference in toxin extractability/accessibility between the strains. RTX toxins in general, and ACT in particular, are known to interact with LPS and other surface molecules, affecting both protein conformation and biological activity (5, 17, 67, 95) . B. hinzii produces an LPS with an O-specific polysaccharide chain which differs significantly from other smooth-type LPS-containing Bordetella strains (such as B. bronchiseptica), as well as B. pertussis, which lacks an O-chain altogether (3, 11, 85) . Thus, the association of B. hinzii ACT with its specific LPS structure, as well as the possibility that the toxin may be nonacylated, could easily alter its ability to be extracted from the membrane.
Although B. hinzii produces a full-length ACT molecule with intact active site domains and the same predicted amino acid sequence as B. pertussis, its biological activities were greatly impaired. B. hinzii ACT was nonhemolytic, unable to elevate intracellular cAMP in host macrophages, and possessed adenylate cyclase activity in the presence of CaM that was approximately 50-fold lower than BP338 (Fig. 5) . The inability to lyse erythrocytes could be explained by an inadequate concentration of added toxin. Numerous previous studies have shown that oligomerization/pore formation is a cooperative process that requires high concentrations of ACT (18, 30, 55) . The inability of purified B. hinzii ACT to intoxicate target cells, however, cannot simply be explained by an insufficient quantity of protein, since B. pertussis ACT can intoxicate at concentrations as low as 50 ng (Fig. 5B) . However, if B. hinzii ACT was either nonacylated or differentially modified, this could explain the lack of toxin activity. It has been shown that nonacylated toxin is still capable of binding CD11b/CD18 receptors on host cells, but it is a nonproductive event eliciting either no intoxication or cytotoxicity (19) or requiring at least a 100-fold higher concentration of ACT to induce cAMP (36) . Our data demonstrating the lack of cyaC expression in B. hinzii (Fig. 7) support the scenario that B. hinzii lacks the enzyme required to fully activate ACT. Examination of purified B. hinzii ACT for posttranslational modifications by mass spectrometry would address whether B. hinzii ACT can be acylated by an alternative acyltransferase and exclusively conclude that the absence of cyaC transcription directly correlates to a nonacylated toxin molecule.
In addition, three lines of evidence in this study directly point to altered affinity for binding calmodulin as a factor in B. hinzii ACT enzymatic activity. When B. hinzii lysates were passed over a CaM-Sepharose matrix, almost 40% of the ACT did not bind (Fig. 4) . This was obviously not due to a matrix capacity problem, since in the same experiment an equivalently packed CaM column bound a much greater amount of ACT from B. pertussis. In Blue-Sepharose competitions, we also showed that the interaction between ACT purified from B. hinzii and the eukaryotic CaM activator was much weaker than the B. pertussis ACT-CaM binding (Fig. 6) . The greatest benefit of using this assay is that one can compare toxins with different individual enzymatic activities to each other. This is because the assay is based on the ability of CaM to compete for ACT in the presence of Blue-Sepharose (50) . Within a sample, the tightness of the CaM-ACT bond dictates whether ACT localizes with the CaM supernatant or Blue-Sepharose pellet fraction. Lastly, when purified by Blue-Sepharose affinity chromatography, B. pertussis ACT enzymatic activity was stimulated by CaM 30-fold more than B. hinzii ACT ( Table 2) . A diminished binding affinity of B. hinzii ACT for CaM would translate into a similarly reduced enzyme activation. An alternative possibility is that B. hinzii ACT requires a factor other than calmodulin for maximal activation. This is not without precedent, since ExoY, the Pseudomonas aeruginosa adenylate cyclase toxin, is dependent upon an as-yet-unidentified host protein distinct from CaM for its enhanced enzymatic activity (93) . One observation that correlates with this concept is that in the absence of CaM, B. hinzii ACT activity was 10-fold higher than that seen with B. pertussis ACT ( Table 2 ). This increased basal adenylate cyclase activity from B. hinzii may indicate a difference in the requirement for or type of activator between the species.
In conclusion, this represents the first functional characterization of a known Bordetella virulence factor now shown to be present in Bordetella hinzii. Although its direct role, if any, in VOL. 187, 2005 B. HINZII ACT 7585 pathogenesis is yet to be determined, we have shown that B. hinzii produces a full-length ACT with enzymatic activity. The variations in toxin and enzyme activities relative to the prototypical B. pertussis ACT seem to be due, at least in part, to both (i) a lack of expression of the gene (cyaC) encoding the enzyme required for activation of ACT and (ii) an altered binding affinity of ACT for host calmodulin. These data are important for defining factors utilized by this microorganism and also as a comparison to B. pertussis. With pertussis cases on the rise in recent years (37) , ACT structure/function studies between the species may shed some light on the innate differences in host niches and disease states for both B. pertussis and B. hinzii.
